Int J Thyroidol.  2018 May;11(1):21-25. 10.11106/ijt.2018.11.1.21.

Effects of Abnormal Thyroid Function Status to Bone Metabolism

• Ahn HY

• KMID: 2428067
• DOI: http://doi.org/10.11106/ijt.2018.11.1.21

Abstract

Thyroid hormone plays an important role in bone remodeling. In overt hyperthyroidism, excess thyroid hormone accelerates bone turnover and shortens the normal bone remodeling cycle, leading osteoporosis and increased fracture risk. Several population and case-control studies have demonstrated that a prior history of hyperthyroidism is an independent risk factor for hip and vertebral fracture. In contrast, bone remodeling cycle is prolonged to almost 2 years with an increase in mineralized cortical bone in overt hypothyroidism. Some cross-sectional and longitudinal studies have suggested that thyroid hormone replacement could decrease bone mineral density in overt hypothyroidism. However, this effect might be interpreted as an adaptive mechanism on decreased bone turnover in preexistent hypothyroidism, and not as thyroid hormone induced bone loss. The effect of thyroid hormone replacement for hypothyroidism on fracture risk has not been investigated well. However, excessive thyroid hormone treatment might be increased the risk of fracture.

Keyword

Hyperthyroidism; Hypothyroidism; Bone density; Fractures; Osteoporosis

MeSH Terms

Bone Density
Bone Remodeling
Case-Control Studies
Hip
Hyperthyroidism
Hypothyroidism
Longitudinal Studies
Metabolism*
Miners
Osteoporosis
Risk Factors
Thyroid Gland*

Reference

1. Korean Endocrine Society. Osteoporosis Fact Sheet 2014. cited May 18, 2018. Available from: http://www.endocrinology.or.kr/ image/main/kor_Osteoporosis_Fact_Sheet2014pdf.

2. Park C, Ha YC, Jang S, Jang S, Yoon HK, Lee YK. The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab. 2011; 29(6):744–751.

3. Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk--a meta-analysis. Thyroid. 2003; 13(6):585–593.

4. Cho BY. Clinical thyroidology. Korea Medical Book. 4th ed. Seoul: Korea;2014. p. 11–24.

5. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002; 23(1):38–89.

6. Forrest D, Reh TA, Rusch A. Neurodevelopmental control by thyroid hormone receptors. Curr Opin Neurobiol. 2002; 12(1):49–56.

7. Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010; 285(33):25103–25108.

8. Capelo LP, Beber EH, Fonseca TL, Gouveia CH. The monocarboxylate transporter 8 and L-type amino acid transporters 1 and 2 are expressed in mouse skeletons and in osteoblastic MC3T3-E1 cells. Thyroid. 2009; 19(2):171–180.

9. Williams AJ, Robson H, Kester MHA, van Leeuwen J, Shalet SM, Visser TJ, et al. Iodothyronine deiodinase enzyme activities in bone. Bone. 2008; 43(1):126–134.

10. O'Shea PJ, Harvey CB, Suzuki H, Kaneshige M, Kaneshige K, Cheng SY, et al. A thyrotoxic skeletal phenotype of advanced bone formation in mice with resistance to thyroid hormone. Mol Endocrinol. 2003; 17(7):1410–1424.

11. Wojcicka A, Bassett JH, Williams GR. Mechanisms of action of thyroid hormones in the skeleton. Biochim Biophys Acta. 2013; 1830(7):3979–3986.

12. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, et al. TSH is a negative regulator of skeletal remodeling. Cell. 2003; 115(2):151–162.

13. Baliram R, Chow A, Huber AK, Collier L, Ali MR, Morshed SA, et al. Thyroid and bone: macrophage-derived TSH-beta splice variant increases murine osteoblastogenesis. Endocrinology. 2013; 154(12):4919–4926.

14. Eriksen EF, Mosekilde L, Melsen F. Kinetics of trabecular bone resorption and formation in hypothyroidism: evidence for a positive balance per remodeling cycle. Bone. 1986; 7(2):101–108.

15. Bassett JH, Williams GR. The molecular actions of thyroid hormone in bone. Trends Endocrinol Metab. 2003; 14(8):356–364.

16. Tuchendler D, Bolanowski M. The influence of thyroid dysfunction on bone metabolism. Thyroid Res. 2014; 7(1):12.

17. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab. 1994; 78(4):955–959.

18. Svare A, Nilsen TI, Bjoro T, Forsmo S, Schei B, Langhammer A. Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study. Eur J Endocrinol. 2009; 161(5):779–786.

19. Bauer DC, Ettinger B, Nevitt MC, Stone KL, Study of. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001; 134(7):561–568.

20. Garin MC, Arnold AM, Lee JS, Robbins J, Cappola AR. Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular health study. J Clin Endocrinol Metab. 2014; 99(8):2657–2664.

21. Lee JS, Buzkova P, Fink HA, Vu J, Carbone L, Chen Z, et al. Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med. 2010; 170(21):1876–1883.

22. Kim MK, Yun KJ, Kim MH, Lim DJ, Kwon HS, Song KH, et al. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Bone. 2015; 71:101–105.

23. Kung AW, Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab. 1996; 81(3):1232–1236.

24. Vestergaard P, Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid. 2002; 12(5):411–419.

25. Vestergaard P, Weeke J, Hoeck HC, Nielsen HK, Rungby J, Rejnmark L, et al. Fractures in patients with primary idiopathic hypothyroidism. Thyroid. 2000; 10(4):335–340.

26. Ko YJ, Kim JY, Lee J, Song HJ, Kim JY, Choi NK, et al. Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women. J Prev Med Public Health. 2014; 47(1):36–46.

27. Murphy E, Gluer CC, Reid DM, Felsenberg D, Roux C, Eastell R, et al. Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab. 2010; 95(7):3173–3181.

28. Noh HM, Park YS, Lee J, Lee W. A cross-sectional study to examine the correlation between serum TSH levels and the osteoporosis of the lumbar spine in healthy women with normal thyroid function. Osteoporos Int. 2015; 26(3):997–1003.

29. Morris MS. The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women. Bone. 2007; 40(4):1128–1134.

30. van der Deure WM, Uitterlinden AG, Hofman A, Rivadeneira F, Pols HA, Peeters RP, et al. Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the Rotterdam Study. Clin Endocrinol (Oxf). 2008; 68(2):175–181.

31. Bassett JH, Williams AJ, Murphy E, Boyde A, Howell PG, Swinhoe R, et al. A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism. Mol Endocrinol. 2008; 22(2):501–512.

32. Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, et al. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J Bone Miner Res. 2005; 20(3):480–486.

33. Martini G, Gennari L, De Paola V, Pilli T, Salvadori S, Merlotti D, et al. The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. Thyroid. 2008; 18(4):455–460.